Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when Evusheld will be available for eligible patients.

Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency on 17 March 2022. However, the initial positive trial data for Evusheld was published prior to the emergence of the Omicron variant.

The UK Health Security Agency has conducted the efficacy of Evusheld against the Omicron variants and initial data for BA.1 and BA.2 has been shared with AstraZeneca. The Department and the National Health Service are identifying the appropriate patient cohorts and approaches to the potential deployment of pre-exposure prophylaxis. We have asked clinicians to advise on the most appropriate option for the NHS in line with the available data, the public health situation and other treatments available. We are therefore unable to confirm an estimated date for the availability of Evusheld.